LWCFA
SUPN icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-34
Closed -$1K – 865
2017
Q3 		$1K Buy
+34
New +$1.47K ﹤0.01% 741

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's SUPN Position: Q4 2017 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 34 shares — an estimated $1K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in SUPN in Q3 2017 and held it in 1 quarter. The position peaked at $1K in Q3 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 34 Supernus Pharmaceuticals shares in Q4 2017, an estimated $1K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Supernus Pharmaceuticals position peaked at $1K in Q3 2017.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.